期刊
PHARMACEUTICALS
卷 15, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ph15030335
关键词
cancer therapeutics; immunotherapy; immunogenic cell death; immune checkpoints; PD-L1/PD-1; CTLA-4
资金
- Dean of Scientific Research (DSR), King Abdulaziz University, Jeddah [IFPRP: 332-188-1442]
Immunotherapy has made significant progress in cancer treatment through blocking immunological checkpoint pathways. Recent studies have shown that combining immune checkpoint inhibitors with other anticancer drugs can improve their effectiveness. Immune checkpoint blockade also aids in inhibiting angiogenesis and enhancing the immune system's efficacy.
Numerous research reports have witnessed dramatic advancements in cancer therapeutic approaches through immunotherapy. Blocking immunological checkpoint pathways (mechanisms employed by malignant cells to disguise themselves as normal human body components) has emerged as a viable strategy for developing anticancer immunity. Through the development of effective immune checkpoint inhibitors (ICIs) in multiple carcinomas, advances in cancer immunity have expedited a major breakthrough in cancer therapy. Blocking a variety of ICIs, such as PD-1 (programmed cell death-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyt-eassociated protein 4 (CTLA-4) has improved the immune system's efficacy in combating cancer cells. Recent studies also supported the fact that ICIs combined with other potent antitumor candidates, such as angiogenic agents, could be a solid promising chemopreventive therapeutic approach in improving the effectiveness of immune checkpoint inhibitors. Immune checkpoint blockade has aided antiangiogenesis by lowering vascular endothelial growth factor expression and alleviating hypoxia. Our review summarized recent advances and clinical improvements in immune checkpoint blocking tactics, including combinatorial treatment of immunogenic cell death (ICD) inducers with ICIs, which may aid future researchers in creating more effective cancer-fighting strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据